Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

News

Down the Road: New Drugs, New Treatment Strategies and Other Changes Coming Your Way

May 5, 2017

Drug Types

  • HIV drug in development
  • Generic HIV drug
  • Hepatitis C drug in development


2017

raltegravir QD A once-daily dose of Isentress. Approval expected in May.

ibalizumab A monoclonal antibody entry inhibitor given by infusion; an injectible may become available. Approval expected in June.

sofosbuvir/valpatasvir/voxilaprevir (GS-9857) A single-tablet regimen (STR) made up of direct-acting antivirals, two of them pangenotypic.

glecaprevir/pibrentasvir A pangenotypic regimen with two direct-acting antivirals.


Advertisement

2018

bictegravir/emtricitabine/tenofovir alafenamide (GS-9883) An STR containing an integrase inhibitor (INSTI) that does not require boosting.

darunavir/cobicistat/tenofovir alafenamide/emtricitabineThe first single-tablet regimen containing a protease inhibitor.

fostemsavirAn HIV entry inhibitor that targets a different step of the viral lifecycle, it offers promise for individuals with virus that has become highly resistant to other HIV drugs.

doravirine/tenofovir disoproxil fumarate/lamivudine A single-tablet regimen containing a non-nuke that may work in those who have developed resistance to other non-nukes, with no food restrictions.

dolutegravir/rilpivirine New co-formulation of already approved INSTI and non-nuke; first STR using only two drugs.

Sustiva (efavirenz) expected to go generic first quarter.

efavirenz/tenofovir disoproxil fumarate/lamivudine expected to be available as generic first quarter; STR similar to Atripla.

Tenofovir disoproxil fumarate/lamivudine expected to be available as generic first quarter; fixed-dose combination similar to Truvada. Not studied or recommended for use as PrEP.


2019

cabotegravir/rilpivirine LA A long-acting injectable containing an INSTI and an NNRTI.

Prezista (darunavir)goes generic.


2020-2021

Emtriva (emtricitabine) goes generic.

Truvada (tenofovir disoproxil fumarate/emtricitabine) goes generic.

Atripla (efavirenz/tenofovir disoproxil fumarate/ emtricitabine) goes generic.

Information courtesy of the Fair Pricing Coalition. For more, go to fairpricingcoalition.org.


Related Stories

New Drugs, New Hope and Possible Timelines (on TheBodyPRO.com)
Five Promising HIV Drugs in the Pipeline (on TheBodyPRO.com)
More on HIV Medications
Drugs in Development: Other New Drugs


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Positively Aware. Visit Positively Aware's website to find out more about the publication.
 

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

 

Advertisement